Omnicell (NASDAQ:OMCL) had its price objective boosted by Oppenheimer to $86.00 in a report published on Friday morning, The Fly reports. The firm currently has an outperform rating on the stock.

OMCL has been the topic of several other research reports. Zacks Investment Research reissued a strong-buy rating and issued a $78.00 target price on shares of Omnicell in a report on Wednesday, November 14th. Wells Fargo & Co upped their price target on shares of Omnicell from $59.00 to $61.00 and gave the company a market perform rating in a research note on Monday, October 29th. BidaskClub downgraded shares of Omnicell from a strong-buy rating to a buy rating in a research note on Thursday, October 4th. Craig Hallum upped their price target on shares of Omnicell from $65.00 to $80.00 and gave the company a buy rating in a research note on Monday, September 17th. Finally, Cantor Fitzgerald upped their price target on shares of Omnicell from $63.00 to $70.00 and gave the company an overweight rating in a research note on Friday, October 26th. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and two have given a strong buy rating to the stock. The stock presently has an average rating of Buy and a consensus target price of $73.75.

Shares of OMCL traded down $0.76 during mid-day trading on Friday, reaching $69.83. The stock had a trading volume of 435,370 shares, compared to its average volume of 351,198. The firm has a market cap of $2.80 billion, a P/E ratio of 387.94, a PEG ratio of 4.22 and a beta of 0.99. Omnicell has a 12 month low of $39.75 and a 12 month high of $79.48. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.78 and a quick ratio of 1.32.

Omnicell (NASDAQ:OMCL) last released its earnings results on Thursday, October 25th. The company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.40 by $0.09. Omnicell had a net margin of 6.11% and a return on equity of 7.91%. The firm had revenue of $204.27 million for the quarter, compared to the consensus estimate of $203.48 million. Equities analysts anticipate that Omnicell will post 1.42 earnings per share for the current year.

In other news, EVP Dan S. Johnston sold 6,250 shares of the company’s stock in a transaction dated Monday, October 15th. The shares were sold at an average price of $63.47, for a total value of $396,687.50. Following the transaction, the executive vice president now directly owns 35,996 shares in the company, valued at $2,284,666.12. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director James T. Judson sold 5,000 shares of the company’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $71.18, for a total transaction of $355,900.00. Following the completion of the transaction, the director now owns 29,952 shares in the company, valued at $2,131,983.36. The disclosure for this sale can be found here. Insiders have sold 19,267 shares of company stock worth $1,309,116 in the last quarter. Company insiders own 3.71% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of Montreal Can purchased a new stake in shares of Omnicell during the second quarter valued at about $102,000. Stone Ridge Asset Management LLC purchased a new stake in shares of Omnicell during the third quarter valued at about $202,000. Everence Capital Management Inc. purchased a new stake in shares of Omnicell during the third quarter valued at about $204,000. Ibex Investors LLC purchased a new stake in shares of Omnicell during the third quarter valued at about $209,000. Finally, Evanston Investments Inc. dba Evanston Advisors purchased a new position in shares of Omnicell in the 3rd quarter valued at approximately $216,000.

Omnicell Company Profile

Omnicell, Inc provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications.

Featured Article: Float

The Fly

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.